Lansoprazole immediate release - TAP/Santarus

Drug Profile

Lansoprazole immediate release - TAP/Santarus

Latest Information Update: 23 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TAP Pharmaceutical Products
  • Developer Santarus; TAP Pharmaceutical Products
  • Class Antiulcers; Benzimidazoles; Gastric antisecretories; Pyridines; Small molecules; Sulfoxides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Gastrointestinal disorders

Most Recent Events

  • 07 Mar 2006 TAP Pharmaceutical Products terminates its sublicence for immediate-release proton pump inhibitor (PPI) technology
  • 07 Mar 2006 Discontinued - Preclinical for Gastrointestinal disorders in USA (unspecified route)
  • 07 Mar 2006 Santarus received a US$10 million milestone payment, plus interest and legal expenses, from TAP Pharmaceutical Products
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top